Search Results
Sep 03, 2025, 06:30 ET Biotechnology Market is Estimated to Reach USD 6.64 Trillion by 2032 | SkyQuest Technology Consulting
promoting market development. Techniques such as CRISPR gene editing, induced pluripotent stem cells (iPSCs), and automated bioreactors have revolutionized the development pipeline. Government funding,
More news about: SkyQuest Technology
Sep 03, 2025, 06:17 ET Red Cross Sickle Cell Initiative reverses decline of African American blood donors, giving over 100,000 patients hope
patients compared to other donors—making the increase in African American donors critical. Patients with sickle cell disease undergoing stem cell or gene therapy treatments also benefit from blood and platelet donations that are closely matched to avoid transfusion-related complications. To help ensure
More news about: American Red Cross
Sep 02, 2025, 15:13 ET Bellwether Wellness and Zone Labs Launch PCOSynergy TTC: The First PCOS Fertility Program to Offer Tech-Enabled Coaching, and Metabolic Engineering® Nutrition
Metabolic Engineering® program — has pioneered strategies that influence gene expression to reduce insulin resistance and inflammation, the two key drivers of PCOS-related infertility.Christine Updegraff, founder
More news about: Zone Labs
Sep 02, 2025, 11:00 ET Learning Genie's Agentic AI Curriculum Tool Achieves ESSA Tier 3 Promising Evidence
Tier 3 Promising Evidence marks a major milestone for advancing high-quality instructional materials powered by AI," said Dr. Gene Shi, CEO of Learning Genie. "As an agentic AI, Curriculum Genie goes beyond assisting teachers—it serves as a trusted partner,
More news about: Learning Genie
Sep 02, 2025, 10:53 ET RareMed Announces Expansion of Relationship with PTC Therapeutics
About PhenylketonuriaPhenylketonuria (PKU) is a rare, inherited metabolic disease, which affects the brain. It is caused by a defect in the gene that helps create the enzyme needed to break down phenylalanine (Phe). If left untreated or poorly managed, Phe—an essential amino acid found in all
More news about: RareMed Solutions
Sep 02, 2025, 10:00 ET GeneseeqPrime® Gains FDA 510(k) Clearance
vitro diagnostic (IVD) test kit that uses next-generation sequencing (NGS) of DNA from FFPE tumor tissue to detect tumor gene alterations across a comprehensive multi gene panel in patients with solid malignant neoplasms.
More news about: Geneseeq Technology Inc.
Sep 02, 2025, 08:41 ET EQT Foundation opens applications for breakthrough research grant in rare diseases
options are limited or nonexistent. At the same time, the rare disease field has given rise to some of the most significant advances in medicine, from gene therapy to RNA-based modulation. This grant call aims to support the next generation of these breakthroughs, solutions that begin with the rare few
More news about: EQT
Sep 02, 2025, 08:30 ET Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a
More news about: Genprex, Inc.
Sep 02, 2025, 08:30 ET Spinogenix Announces Positive Type C Meeting with the FDA for SPG601 in Patients with Fragile X Syndrome (FXS)
not only impacts individuals but entire families, economically and emotionally" FXS, a genetic disorder caused by the silencing of the Fmr1 gene, is the leading inherited form of intellectual disability and a major known cause of autism. It can produce a wide range of disabling symptoms, with
More news about: Spinogenix
Sep 02, 2025, 08:11 ET Diversified Transportation Awarded Industrial Busing Contract for Barrick Mining Corporation and Nevada Gold Mines, the World's Largest Gold-Producing Complex
Mines for this opportunity and look forward to delivering reliable and safe transportation services to their teams," said Gene Kowalczewski, CEO of Student Transportation of America. "Our continued investment in Nevada reflects STA's
More news about: Student Transportation of America
Sep 01, 2025, 11:00 ET Regenerative Medicine Market is Estimated to Grow at a CAGR of 16% During 2025-2032 | SkyQuest Technology Consulting
Funding: U.S.-based pharmaceutical giants and biotech startups are investing heavily in gene therapy, cell therapy, and tissue engineering.FDA Approvals Driving Adoption: Recent approvals, including Gilead Sciences' pioneering gene therapy for rare neurological conditions, highlight the U.S. regulatory
More news about: SkyQuest Technology
Sep 01, 2025, 10:30 ET Contract Research Organization (CRO) Services Market worth $125.95 billion in 2030 with 8.3% CAGR | MarketsandMarkets™
digital tools that enhance patient recruitment, eConsent, and remote data capture. ICON's therapeutic strengths include oncology, rare diseases, cell and gene therapy, vaccines, and infectious diseases, supported by specialized biomarker and late-phase capabilities. The acquisition of PRA Health Sciences (US)
More news about: MarketsandMarkets
Aug 29, 2025, 17:35 ET Galderma reúne mais de 500 médicos da América Latina para apresentar as últimas novidades em estética injetável
HIV-infected patients: results of the openlabel study VEGA.5. Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapatite (CaHA) in the treatment of nasolabial folds. Poster presented at the IMCAS World
More news about: Galderma
Aug 29, 2025, 02:00 ET Traitement clinique de la drépanocytose par édition de base de haute précision -- le CS-101 de CorrectSequence Therapeutics obtient des résultats prometteurs chez la première patiente
qui seraient porteurs d'une variante pathogène. Chaque année, environ 400 000 nouveau-nés sont touchés. La drépanocytose, causée par des mutations du gène de la bêta-globine, entraîne la formation de globules rouges anormaux en forme de faucille, ce qui se traduit par une anémie chronique, des crises douloureuses
More news about: CorrectSequence Therapeutics
Aug 29, 2025, 01:23 ET UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Rodriguez N, et al[23] AAV gene therapy at neonatal age in a mouse model of STXBP1 haploinsufficiency
More news about: UCB
Aug 29, 2025, 01:15 ET UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Rodriguez N, et al[23] AAV gene therapy at neonatal age in a mouse model of STXBP1 haploinsufficiency
More news about: UCB
Aug 28, 2025, 17:46 ET Global Pharmaceutical Contract Manufacturing Market to Surpass the USD 360 Billion Mark by 2032 | DelveInsight
companies are significantly bolstering their R&D pipelines, particularly in areas such as biologics, biosimilars, and advanced modalities, including gene and cell therapies. LAS VEGAS,
More news about: DelveInsight Business Research, LLP
Aug 28, 2025, 12:03 ET Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit:
More news about: Piramal Pharma Solutions
Aug 28, 2025, 11:58 ET Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit:
More news about: Piramal Pharma Solutions
Aug 28, 2025, 10:45 ET Life Science Tools Market to Grow at a CAGR of 10.81% from 2025 to 2032 | SkyQuest Technology Consulting
microscopy, next generation sequencing, PCR & qPCR, nucleic acid preparation, nucleic acid microarray, sanger sequencing, transfection devices & gene delivery technologies, NMR, other separation technologies, other products & services. Based on technology, the market is segmented into genomic
More news about: SkyQuest Technology
Aug 28, 2025, 10:44 ET FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
local recurrence or metastasis is not only practice-changing for physicians who treat SCC, but also life-changing for their patients." The 40-gene expression profile test uses a patient's tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis and stratify patients
More news about: USA News Group
Aug 28, 2025, 10:31 ET Cancer Diagnostics Market to Grow at a CAGR of 9.4% from 2025 to 2032 | SkyQuest Technology Consulting
crucial role in helping cement the dominance of the United States going forward. Rising use of personalized medicine and gene therapies for the treatment of cancer is also expected to create new business scope for cancer diagnostics companies. High awareness among patients
More news about: SkyQuest Technology
Aug 28, 2025, 10:00 ET Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs
By safely and efficiently expanding human HSCs, Celaid aims to provide the next generation of cell and gene therapy products for cell therapy targeting hematologic disease, ex vivo HSC gene therapy for genetic disorders, and angiogenesis for ischemic diseases. About AGC AGC
More news about: Celaid Therapeutics Inc.
Aug 28, 2025, 09:28 ET Made Scientific Launches Scientific Advisory Board with Appointments of Distinguished Cell Therapy Innovators Miguel Forte, M.D., Ph.D., Paul K. Wotton, Ph.D., Shishir Gadam, Ph.D., and Young K. Hong, M.D.
FORTE Miguel Forte, M.D., Ph.D., is CEO of Kiji Therapeutics and President of the International Society for Cell & Gene Therapy (ISCT). Prior to joining Kiji Therapeutics, he was CEO of Bone Therapeutics and Zelluna Immunotherapy, and CMO/COO of TxCell. Dr. Forte also
More news about: Made Scientific, Inc.
Aug 28, 2025, 08:35 ET The Perch at Peacock Inn to Host "Great Growths of Burgundy & Bordeaux" Wine Pairing Dinner and Rare Vintage Silent Auction
an exceptional, thoughtful collection that inspires discovery," said John Pelehaty, Hospitality Beverage Manager for Gene Hospitality. "We strive to ensure that every glass tells a story and every sip becomes a lasting memory for our guests." Event Details:
More news about: Genesis Hospitality